Dzhndoian Z T
Georgian Med News. 2011 Dec(201):48-51.
the determination of serum amyloid A (SAA) protein concentrations in FMF patients: the colchicine-resistant patients and the patients responded to the different doses of colchicine, and estimation of the risk of the amyloidosis development in these patients. SAA concentration was measured in 58 FMF patients: 23 colchicine-resistant patients without amyloidosis and 35 patients responded to the different doses of colchicine also without amyloidosis as a group of comparison. Serum SAA concentration was measured by ELISA (Enzyme Linked-Immuno-Sorbent-Assay) method using "ANOGEN" kit (Canada). Serum SAA concentration was the same in both groups of the patients: colchicine-resistant patients and patients responded to the different doses of colchicine. The findings of our study indicate that the risk of the amyloidosis development is the same in colchicine-resistant patients and patients responded to the different doses of colchicine.
对家族性地中海热（FMF）患者血清淀粉样蛋白A（SAA）蛋白浓度的测定：对秋水仙碱耐药的患者以及对不同剂量秋水仙碱有反应的患者，并评估这些患者发生淀粉样变性的风险。对58例FMF患者进行了SAA浓度测定：23例无淀粉样变性的秋水仙碱耐药患者和35例对不同剂量秋水仙碱有反应且同样无淀粉样变性的患者作为对照组。使用加拿大“ANOGEN”试剂盒通过酶联免疫吸附测定（ELISA）法测量血清SAA浓度。两组患者（秋水仙碱耐药患者和对不同剂量秋水仙碱有反应的患者）的血清SAA浓度相同。我们的研究结果表明，秋水仙碱耐药患者和对不同剂量秋水仙碱有反应的患者发生淀粉样变性的风险相同。
